综述:当前及在研乙型肝炎病毒治疗的临床药理学
本文综述了当前和在研(≥2期)乙型肝炎病毒(HBV)治疗药物的药理学、药物相互作用、疗效、安全性及作用机制。在研药物如Bulevirtide、JNJ-56136379、ABI-H0731、REP-2139和Inarigivir可降低HBV DNA/RNA,其中REP-2139、Inarigivir和ARO-HBV可诱导HBsAg丢失,但部分药物存在安全性担忧。
要点
- 在研药物Bulevirtide等降低HBV DNA/RNA的效力优于当前核苷(酸)类似物。
- REP-2139、Inarigivir和ARO-HBV可诱导HBsAg丢失,可能提高功能性治愈率。
- 部分在研药物存在安全性问题,如Bulevirtide升高胆汁酸、REP-2139引起肝酶 flare。
核心结论
- 在研HBV治疗药物有前景,增加HBsAg丢失可能使更多患者实现功能性治愈。
- 许多知识空白仍存在,包括在HBV、肝硬化和肾功能损害患者中的药代动力学、在研药物间的相互作用潜力、风险-获益特征以及与老龄化合并症用药的潜在药物相互作用。
研究设计与样本
- 描述性综述,使用PubMed和Google检索文献/会议论文,纳入在HBV感染者中具有疗效和安全性数据的在研化合物(≥2期)。
主要发现
- Bulevirtide、JNJ-56136379、ABI-H0731、REP-2139和Inarigivir降低HBV DNA/RNA,效力优于当前核苷(酸)类似物。
- REP-2139(25%-75%的患者,治疗20-48周)和Inarigivir(26%的患者,治疗12-24周)诱导HBsAg丢失。
- ARO-HBV在85%的患者中降低HBsAg(>1.5 log10 UI/mL,治疗12周)。
- 部分在研药物存在安全性担忧,如Bulevirtide升高胆汁酸、REP-2139引起肝酶 flare,需与当前疗法进行风险-获益评估。
- Bulevirtide、JNJ-56136379、ABI-H0731有单次和多次给药药代动力学数据;REP-2139、ARO-HBV、Inarigivir无此类数据。
关键数值与推荐
- REP-2139:25%-75%的患者HBsAg丢失,治疗20-48周。
- Inarigivir:26%的患者HBsAg丢失,治疗12-24周。
- ARO-HBV:85%的患者HBsAg降低>1.5 log10 UI/mL,治疗12周。
临床怎么用
- 在研药物可能提高HBV功能性治愈率,但需评估安全性风险并与当前疗法进行风险-获益比较。
- 临床应用中需关注在研药物的药代动力学知识空白,特别是在肝硬化、肾功能损害患者及合并用药时的相互作用潜力。
局限性
- 许多知识空白仍存在,包括在HBV、肝硬化和肾功能损害患者中的药代动力学、在研药物间的相互作用潜力、风险-获益特征以及与老龄化合并症用药的潜在药物相互作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment of hepatitis B virus (HBV) infection with current therapy suppresses HBV DNA, but loss of hepatitis B surface antigen (HBsAg; functional cure), is rare. Multiple compounds are under investigation. AIMS: To describe the pharmacology, including drug interactions, efficacy, safety and mechanisms of action of investigational compounds for HBV infection. METHODS: Descriptive review using PubMed and Google to identify literature/conference papers on investigational compounds (≥Phase 2) with data on efficacy and safety in HBV-infected patients. RESULTS: Bulevirtide, JNJ-56136379, ABI-H0731, REP-2139, and inarigivir decrease HBV DNA/RNA, with greater potency than current nucleos(t)ide analogues. REP-2139 (25%-75% of patients, 20-48 weeks treatment) and inarigivir (26% of patients, 12-24 weeks treatment) induce HBsAg loss. ARO-HBV reduced (>1.5 log10 UI/mL) HBsAg in 85% of patients (12 weeks treatment). There are some safety concerns with investigational agents (e.g., increased bile acids with bulevirtide, and liver enzyme flares with REP-2139) which will require a risk benefit assessment compared with current therapies. Single and multidose pharmacokinetic data are available for bulevirtide, JNJ-56136379, ABI-H0731; no such data are available for REP-2139, ARO-HBV, inarigivir. Initial drug interaction assessments have been performed with bulevirtide and inarigivir (only in vitro). CONCLUSIONS: There are promising investigational therapies for HBV infection. Increasing the potential for HBsAg loss may result in more patients achieving functional cure. However, many knowledge gaps remain such as pharmacokinetics in those with HBV, cirrhosis and renal impairment but also the interaction potential between investigational therapies, risk-benefit profiles, and potential for drug interactions with medications used to treat comorbidities associated with aging.
引用
- Smolders EJ, Burger DM, Feld JJ, et al. Review article: clinical pharmacology of current and investigational hepatitis B virus therapies. Aliment Pharmacol Ther. 2019. PMID: 31840863. doi:10.1111/apt.15581
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。